Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
M&A activity
confidence 92%
filed 2026-09-28
EX-99.1
Foresight announced entry into a non-binding term sheet for acquisition of a 50.01% controlling interest in a European data center development company with two projects in Poland totaling 270 MW capacity. This represents a material acquisition activity that would expand the company into a new market segment (data centers) and provide controlling interest in a significant infrastructure platform, meeting the definition of ma_activity under Items 1.01/2.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-28
Item 1.01
Azitra entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners on September 28, 2026, permitting the issuance of up to $3.5 million in common stock shares. This is a classic dilutive equity issuance under an effective S-3 registration statement, with the Company retaining discretion to sell shares over time through an agent. The 3.0% commission structure and use of proceeds for working capital are typical ATM characteristics, and such offerings materially dilute existing shareholders and signal capital-raising activity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-28
WeShop entered into an Ordinary Shares Purchase Agreement with Roth Principal Investments on September 9, 2026, granting the Company the right to sell up to $25,000,000 of newly issued Class A ordinary shares at the Company's sole discretion over 36 months. This is a classic at-the-market (ATM) or equity line of credit arrangement—an unregistered continuous offering of equity securities. The filing explicitly notes the transaction is subject to Nasdaq's 19.99% Exchange Cap limitation and contemplates potential shareholder approval or reliance on foreign private issuer exemptions, confirming the dilutive nature. The $500,000 commitment fee and $75,000 legal reimbursement further evidence a material capital-raising transaction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-28
J-Star entered into an equity purchase agreement with Hudson Global Ventures on September 24, 2026, granting the investor the right to purchase up to $35 million of Class A ordinary shares over 36 months at a discounted price (95% of average of three lowest traded prices), plus warrants for 525,000 shares. This is a classic at-the-market (ATM) or PIPE-like arrangement that creates significant dilution risk to existing shareholders and is material to investor assessment of capital structure and ownership.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-09-28
Item 5.02
The Compensation Committee adopted a Senior Management Change of Control Severance Policy on September 25, 2026, establishing compensatory arrangements for the CEO, President, EVPs, and SVPs (all named executive officers). The policy specifies severance multiples (2.0x for CEO, 1.5x for others), equity acceleration provisions, and COBRA continuation benefits triggered by qualifying terminations in connection with a change of control. This is a material disclosure of executive compensation arrangements under Item 5.02(e).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-28
The filing discloses an exchange agreement in which CEO Arthur Sams converted $614,700 of debt into 683 shares of Series A Convertible Preferred Stock and a warrant to purchase 382,276 common shares. While structured as a debt-to-equity conversion, Item 3.02 explicitly incorporates the disclosure, and the press release emphasizes the issuance of equity securities (preferred shares and warrants) to address balance sheet and Nasdaq compliance issues. This is a material dilutive issuance of equity, though the debt conversion aspect is also significant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-28
The filing discloses amendments to multiple series of convertible promissory notes (Bridge Notes and September Notes) and warrants executed beginning September 22, 2026, with the September Note Amendments becoming effective on September 28, 2026. While the original issuances occurred earlier, the material amendments modify critical terms including anti-dilution provisions, Floor Price adjustments, and make-whole payment provisions. The amendments to convertible debt instruments constitute material modifications to direct financial obligations, most closely aligned with debt_issuance in the taxonomy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-28
Item 8.01
The filing discloses entry into a non-binding term sheet for a material acquisition: AIxCrypto Holdings (AIXC) proposes to acquire Faraday Future's robotics business for approximately $200 million in stock consideration. Although the term sheet is non-binding, the transaction represents a fundamental strategic transformation of the company (including a name change from AIxCrypto to FF EAI Robotics Ecosystem and ticker change to FFR), involves a substantial acquisition price relative to the company's ~$55 million pre-closing equity valuation, and requires special committee and stockholder approvals. This is a classic M&A activity disclosure under Item 8.01 (Other Events) that would materially affect investor assessment of the registrant's direction and value.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-28
The filing discloses that Nasdaq's Listing and Hearing Review Council has affirmed the delisting of Bayview Acquisition Corp's securities effective after the Company failed to complete its business combination by June 19, 2026. The Company anticipates Nasdaq will file Form 25-NSE to remove the securities from listing and registration, with the Company planning to move to OTC Markets trading. This is a material delisting event under Item 3.01.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-28
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release announcing fiscal 2026 full-year and Q4 results. The filing reports record revenue of $74.4 million (12.5% growth), operating income nearly doubling to $6.9 million, and strong cash generation of $13.9 million operating cash flow. The company also introduced fiscal 2027 guidance. This is a standard earnings release disclosure material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-28
EX-99.1
Julong announced a private placement of 750,000 Class A ordinary shares at US$0.300 per share and 2,250,000 pre-funded warrants at US$0.299 per warrant, generating gross proceeds of US$897,750. This is an unregistered sale of equity securities under Regulation D, with the securities explicitly stated as not registered under the Securities Act of 1933. The pre-funded warrants are immediately exercisable at US$0.001 per share, creating significant dilution to existing shareholders. This is a classic dilutive issuance event material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-09-28
Item 4.01
The filing discloses the dismissal of Boladale Lawal & Co. as the Company's independent registered public accounting firm effective September 22, 2026, and the engagement of TQ International, PLLC as the successor auditor. This is a classic auditor change under Item 4.01. Although the prior auditor's report included explanatory language regarding substantial doubt about going concern, the primary disclosed event is the change in auditors, not the going-concern matter itself (which is historical and already reflected in prior audit reports).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-28
Item 7.01
The Company declared a monthly "base" cash distribution of $0.03242 per share and a quarterly "bonus" cash distribution of $0.04333 per share, totaling an annualized distribution rate of 14.46% based on NAV. This is a routine but material disclosure of dividend and distribution declarations to common shareholders, which is the core business of a closed-end fund and directly affects shareholder returns.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-28
Item 1.01
This disclosure describes the termination of purchaser termination rights under a purchase and sale agreement to sell the Company's portfolio of 40 outpatient medical facilities for approximately $531 million, with expected closing in Q4 2026. This constitutes a material disposition/sale transaction that would significantly affect the registrant's asset base and financial position, fitting squarely within the ma_activity category for entry into and progression of a material acquisition or disposition.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-09-28
Item 8.01
News Corp disclosed ongoing execution of its $1 billion share repurchase program authorized July 15, 2025, with approximately $498.9 million deployed to date across Class A and Class B common stock. The Item 8.01 disclosure includes daily buy-back notifications to the ASX showing 12.4 million Class A shares and 62,323 Class B shares repurchased on September 25, 2026, for approximately $327 million in aggregate consideration. Share repurchases constitute a return of capital to shareholders and are material to investors assessing capital allocation and shareholder value enhancement.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-09-28
Item 8.01
News Corporation discloses daily share repurchase activity under its authorized $1 billion repurchase program, with specific transaction details including 12.5 million Class A shares and 62,323 Class B shares purchased on 28 September 2026 for approximately $328.8 million in aggregate consideration. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as a return of capital program, distinct from routine administrative disclosures.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-28
Item 7.01
The Board of Trustees declared a regular distribution of $0.19 per common share, payable to shareholders of record as of September 30, 2026, with payment on or about October 30, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-28
Item 8.01
The Company disclosed its NAV per share ($22.84 as of August 31, 2026), aggregate NAV (~$949.4 million), investment portfolio fair value (~$1,881.1 million), debt outstanding (~$938.6 million), leverage ratio (~0.97x), and available debt capacity (~$1,510.0 million), along with updates on share issuances and the continuous private offering.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-28
EX-99.1
Gold Fields submitted a non-binding indicative proposal on 13 September 2026 to acquire 100% of Northern Star Resources Ltd by scheme of arrangement for A$27.00 per share (0.3125 Gold Fields shares plus A$7.25 cash per Northern Star share), with estimated synergies of US$4–5 billion. Although the Northern Star Board declined further engagement on 24 September 2026, this disclosure of entry into material acquisition discussions with specific terms, valuation, and strategic rationale constitutes a reportable M&A activity event under the taxonomy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-28
Item 8.01
Strive announced a bitcoin purchase of 1,107 BTC at ~$85,396 per coin during September 21-25, 2026, along with updated holdings of cash, bitcoin, STRC Stock, and share counts. This is a material operational/strategic disclosure of the company's bitcoin treasury strategy execution and capital allocation, consistent with Strive's stated business model as a bitcoin-focused investment company. While not fitting a specific named event type, this is clearly an operational/strategic matter affecting the company's asset composition and investor assessment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-28
Item 5.02
Chirantan 'CJ' Desai, President and Chief Executive Officer of MongoDB, notified the Company of his intent to resign effective September 28, 2026. The departure of a sitting CEO is material to investors and affects the total mix of information about the registrant's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-28
Item 5.02
James C. Clancy was appointed Chief Operating Officer of Quantum Corporation, effective September 28, 2026. The appointment includes a compensation package of $400,000 base salary, 60% target bonus, 150,000 RSUs, and 400,000 stock options, along with change-of-control severance arrangements. Clancy brings extensive executive experience in data management and storage and previously served on Quantum's Board.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-28
Item 1.01
RideNow Group entered into a $220 million senior secured term loan credit agreement on September 25, 2026, to refinance an existing credit facility, with interest rates of 7.375%–8.375% plus SOFR, maturity in September 2031, and specified covenants. The company also amended and restated three unsecured promissory notes totaling approximately $10 million. This represents a material refinancing and restructuring of the company's debt obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-09-28
Item 1.02
RideNow Group terminated a material definitive agreement, as disclosed in Item 1.02 with cross-reference to Item 1.01. The termination likely concerns a material acquisition, disposition, merger, or change-of-control transaction that has been unwound or terminated.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-28
Item 8.01
RideNow Group is in advanced discussions with Wells Fargo regarding a $50 million senior secured asset-based revolving credit facility (ABL Facility) intended to refinance existing term loans and fund working capital, though no binding commitment has been made.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-28
Item 5.02
The Board approved amendments to the 2026 Executive Bonus Plan that modify compensatory arrangements for the Chief Executive Officer and Chief Financial Officer, increasing their maximum annual bonus eligibility to 59% and 56% of base salary respectively based on new performance metrics (net income above $10,000,000 and Section 45Z tax credits). This is a direct disclosure of executive compensation plan amendments under Item 5.02(e).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-28
Item 7.01
The Board declared a regular distribution of $10,710,000 (approximately $0.52 per share) payable to shareholders, with a record date of September 30, 2026 and payment date of November 16, 2026. This is a straightforward dividend distribution disclosure, material to investors as it affects shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
This is a clear disclosure of shareholder vote results from a special meeting held on September 22, 2026. The filing reports voting outcomes on two proposals: (1) approval of a reverse stock split (1-for-5 to 1-for-20 ratio) with 114,398,602 votes for and (2) approval of adjournment with 114,344,814 votes for. Both proposals passed with overwhelming majorities (>98% approval). A reverse stock split is a material capital structure event that would affect all shareholders, making this disclosure material to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-28
Item 1.01
Voyager Technologies issued $402.5 million aggregate principal amount of 0% Convertible Senior Notes due 2032 on September 28, 2026, pursuant to an indenture with U.S. Bank Trust Company. The notes were offered as a private placement to qualified institutional buyers under Section 4(a)(2) and Rule 144A, with up to 12,818,457 shares of Class A common stock potentially issuable upon conversion at a $40.82 conversion price.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-28
Item 5.02
The disclosure centers on the adoption of the Workhorse Group Inc. Value Creation Incentive Plan (VCIP) and grants of performance awards to named executives Scott Griffith (CEO, $15 million target) and Jody Davis (CFO, $6.5 million target) based on achievement of specified performance goals over a five-year period. This is a compensatory arrangement for directors and officers under Item 5.02(e), not a departure or appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-28
Item 5.02
The filing discloses multiple executive and board appointments on September 25, 2026: Dan Rogers appointed as Board Chair (in addition to CEO role), Tom Berquist and Jerry Ting appointed as directors, and Heather Le appointed as Chief Accounting Officer and Principal Accounting Officer. While the section also mentions Dustin Moskovitz's transition from Chair to director (a departure from the Chair role), the principal disclosed actions center on the appointments of new leadership roles. The appointment of a new Chief Accounting Officer and two experienced directors with significant software industry backgrounds, combined with the CEO assuming the Chair role, represents material governance and leadership changes affecting the company's strategic direction.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-09-28
Item 8.01
Ready Capital closed a $225.0 million private placement of 10.00% Senior Secured Notes due 2031 on September 28, 2026, creating a new direct financial obligation. While the filing also discloses a concurrent redemption of $350.0 million in existing notes, the principal disclosed action is the issuance of new debt, which is material to investors assessing the company's capital structure and financial obligations.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 92%
filed 2026-09-28
The 6-K furnishes results of Coincheck Group's annual general meeting held September 25, 2026, disclosing shareholder votes on nine proposals including adoption of annual accounts, director appointments (including new director Shumpei Tatebayashi from KDDI Corporation), auditor reappointment, and authorizations for share issuance and repurchase. This is a classic shareholder_vote_results disclosure. The appointment of Tatebayashi and the resignation of Executive Chairperson Takashi Oyagi (disclosed separately on September 17, 2026) are material governance changes, making the vote results material to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-28
Item 8.01
Camp4 Therapeutics disclosed material updates on its clinical development pipeline at an Analyst Day meeting, including detailed information on the ASCEND Phase 1/2 clinical trial for CMP-002 in SYNGAP1-related disorder (with expected first patient dosing by end of 2026 and topline data in H1 2028) and advancement of a preclinical SHANK3 program for Phelan-McDermid Syndrome.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-28
EX-99.1
This press release announces the initiation of a Phase Ia global clinical trial for HMPL-A830, a first-in-class KRAS-EGFR antibody conjugate therapy in solid tumors, with first patient dosed on September 24, 2026. The disclosure also references a September 3, 2026 exclusive development and license agreement with a GSK subsidiary granting worldwide rights (excluding Greater China) to develop and commercialize HMPL-A830. This is a material operational and strategic milestone—a significant clinical development advancement and partnership arrangement—that does not fit the specific event categories of M&A activity (the license agreement is a development partnership, not an acquisition or change of control) or earnings/financial disclosure. It represents a material operational milestone affecting the company's drug development pipeline and commercial strategy.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-28
EX-99.1
Vox Royalty Corp. announced entry into a binding agreement for its subsidiary to acquire a 0.75% net smelter return royalty over the Sorby Hills silver-lead project in Western Australia for $13 million in cash. This is a material acquisition of a royalty interest in a construction-stage mining project expected to produce near-term precious metals revenue, fitting the definition of ma_activity (entry into a material acquisition). The transaction is binding, subject only to customary conditions precedent and regulatory approval, with expected completion in Q4 2026.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-28
The 6-K announces admission to trading of €850 million in debt securities issued by IHG Finance LLC (a wholly owned subsidiary of InterContinental Hotels Group PLC): EUR 350 million 4.000% Notes due 2029 and EUR 500 million 4.625% Notes due 2033, both guaranteed by the parent company. This constitutes creation of a material direct financial obligation and is a debt issuance event under Item 2.03 equivalent.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-09-28
This is a Notice of Redemption for US$2.5 billion of senior unsecured notes due 2027, issued by HSBC Holdings plc. While technically a redemption (retirement) of existing debt rather than issuance of new debt, it represents a material financial obligation event involving the creation or modification of a direct financial obligation. The redemption price of par (US$1,000 per US$1,000 principal) plus accrued interest payable on 23 November 2026 is a material capital event for a major global financial institution.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-28
Item 5.02
Michael W. Pugh's retirement from the Board of Directors on September 24, 2026, effective immediately, is the principal disclosed action in subsection (b). While subsection (e) discloses plan amendments increasing share authorization, the departure of a director is the more salient event affecting investor assessment of the company's governance and board composition. The retirement was triggered by mandatory retirement age provisions in the bylaws.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-28
Item 1.01
The Company amended its previously completed acquisition of 51% membership interests in GlobeTopper, LLC by restructuring the $500,000 deferred consideration from restricted stock issuance to cash payments over time, evidenced by a secured promissory note with pledge of collateral and default/rescission remedies.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-28
Item 7.01
IQSTEL Digital disclosed an illustrative economic model for a contemplated microdrama subscription service, including projected subscriber levels, pricing, revenue-sharing arrangements, and profit-contribution estimates, representing a material new business opportunity and diversification initiative.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-28
Item 7.01
The disclosure announces the first patient dosing in a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy, a material clinical development milestone for a clinical-stage biopharmaceutical company. This represents significant operational progress in advancing the company's lead product candidate and clinical pipeline, with initial data expected in H1 2027. While this is a clinical milestone rather than a financial event, earnings release, or governance matter, it constitutes a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline advancement.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-28
EX-99.1
This is a notification of a relevant change to a significant shareholder under AIM Rules. BlackRock, Inc. crossed a notification threshold on September 23, 2026, with a resulting position of 6.96% of voting rights (5.03% direct shares plus 1.92% through financial instruments). While not a traditional governance event like an executive appointment or board change, this disclosure of a major shareholder crossing a regulatory threshold is a governance matter affecting the company's shareholder structure and control dynamics, material to investors assessing ownership concentration and potential influence.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-28
Item 2.02
This Item 2.02 discloses Precision Optics' fourth quarter and fiscal year 2026 financial results via a press release attached as Exhibit 99.1. The filing reports quarterly record revenue of $8.8 million (42% growth YoY), fiscal year revenue of $31.5 million (65% growth), and provides fiscal 2027 guidance of $30–$33 million revenue and $(1.2)–$(1.7) million Adjusted EBITDA. The earnings release is the core disclosure, making this a standard earnings_release event that would materially affect investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-28
Item 7.01
Burford Capital disclosed a jury verdict in a patent litigation matter (Taction Technology v. Apple) awarding $5.7 billion in damages, with Burford's entitlement valued at $1.4 billion. The filing explicitly states this represents "one of the largest patent verdicts in U.S. history" and is material to investors' assessment of the company's financial position and litigation portfolio performance. While the verdict is subject to post-trial motions and appellate review, the disclosure of this significant litigation outcome is the core material event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-28
Item 8.01
Adicet Bio announced positive Phase 1 clinical data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis, demonstrating 54% DORIS remission and 50% complete renal response at 12 months with a favorable safety profile. The company plans to initiate pivotal study start-up activities in Q4 2026, representing a material clinical development milestone for the company's pipeline.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-28
Item 8.01
The disclosure reports that Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)) following a prior non-compliance notice dated April 8, 2026, and a 1-for-80 reverse stock split executed on September 10, 2026. This is a delisting-risk resolution: the company was at risk of delisting due to failure to maintain a $1.00 minimum bid price for 30 consecutive business days, but has now cured that deficiency through the reverse split and price recovery. Material to investors as it directly addresses the company's continued listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
Anavex held its 2026 Annual Meeting on September 24, 2026, where shareholders voted on the election of six directors and ratification of Grant Thornton LLP as independent auditor. The Company's slate of director nominees defeated a contested slate of six PVG-nominated candidates, with detailed voting tallies certified by the Inspector of Elections.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-28
Item 5.01
The election of new directors at the 2026 Annual Meeting caused Incumbent Directors to fall below a majority, triggering a change-of-control event under the Company's Incentive Plans and employment agreements. This Board Change CIC immediately vested all outstanding equity awards and constitutes a material change in control affecting the registrant's governance and contractual obligations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-28
Item 8.01
This Item 8.01 discloses two major operational milestones: (1) FDA approval of Atebrioz (zilurgisertib) for FOP on September 25, 2026, with commercial availability expected in October 2026, and (2) announcement on September 28, 2026 that brelovitug met its primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta, with BLA submission expected in H1 2027 and commercial launch in Q4 2027. These are material regulatory and clinical achievements that advance the company's pipeline and revenue prospects (estimated >$200M for Atebrioz and >$1B for brelovitug annually), but they do not fit neatly into the specific event categories (not earnings, not M&A, not impairment, not litigation). The disclosure centers on product development milestones and regulatory progress rather than a single discrete event type, making operational_other the most appropriate classification.
View raw filing on EDGAR →